ZA200206470B - 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation. - Google Patents
1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation.Info
- Publication number
- ZA200206470B ZA200206470B ZA200206470A ZA200206470A ZA200206470B ZA 200206470 B ZA200206470 B ZA 200206470B ZA 200206470 A ZA200206470 A ZA 200206470A ZA 200206470 A ZA200206470 A ZA 200206470A ZA 200206470 B ZA200206470 B ZA 200206470B
- Authority
- ZA
- South Africa
- Prior art keywords
- microglia activation
- illnesses associated
- treating illnesses
- benzimidazoles
- diaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10002898 | 2000-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206470B true ZA200206470B (en) | 2004-04-28 |
Family
ID=7628535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206470A ZA200206470B (en) | 2000-01-14 | 2002-08-13 | 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation. |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1246808B1 (sr) |
| JP (1) | JP2003523961A (sr) |
| KR (1) | KR100703908B1 (sr) |
| CN (1) | CN1301975C (sr) |
| AT (1) | ATE520669T1 (sr) |
| AU (1) | AU782993B2 (sr) |
| BG (1) | BG65858B1 (sr) |
| BR (1) | BR0107628A (sr) |
| CA (1) | CA2396227C (sr) |
| CY (1) | CY1112962T1 (sr) |
| CZ (1) | CZ303726B6 (sr) |
| DK (1) | DK1246808T3 (sr) |
| EA (1) | EA006302B1 (sr) |
| EE (1) | EE05515B1 (sr) |
| ES (1) | ES2372026T3 (sr) |
| HR (1) | HRP20020664B1 (sr) |
| HU (1) | HU228366B1 (sr) |
| IL (2) | IL150150A0 (sr) |
| ME (1) | MEP13308A (sr) |
| MX (1) | MXPA02005742A (sr) |
| NO (1) | NO326408B1 (sr) |
| NZ (1) | NZ519326A (sr) |
| PL (1) | PL209573B1 (sr) |
| PT (1) | PT1246808E (sr) |
| RS (1) | RS51860B (sr) |
| SI (1) | SI1246808T1 (sr) |
| SK (1) | SK287527B6 (sr) |
| TW (1) | TWI287005B (sr) |
| UA (1) | UA75589C2 (sr) |
| WO (1) | WO2001051473A1 (sr) |
| ZA (1) | ZA200206470B (sr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10134775A1 (de) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| US6855714B2 (en) | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| US6903126B2 (en) | 2001-07-09 | 2005-06-07 | Schering Ag | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| DE10135050A1 (de) * | 2001-07-09 | 2003-02-06 | Schering Ag | 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| DE10207844A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| DE10207843A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
| US6962932B2 (en) | 2002-02-15 | 2005-11-08 | Schering Aktiengesellschaft | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| US7375228B2 (en) * | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| SE0302573D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302570D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| RU2374234C2 (ru) | 2004-09-24 | 2009-11-27 | Астразенека Аб | Бензимидазольные производные, содержащие их композиции, их получение и применение |
| TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
| TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
| JP5255994B2 (ja) * | 2008-11-04 | 2013-08-07 | 国立大学法人 岡山大学 | 核内受容体リガンド |
| WO2012012478A1 (en) | 2010-07-21 | 2012-01-26 | Merck Sharp & Dohme Corp. | Aldosterone synthase inhibitors |
| CN102382102B (zh) * | 2010-09-06 | 2014-01-08 | 中国科学院广州生物医药与健康研究院 | 一种酰胺类化合物 |
| EP2814486B8 (en) * | 2012-02-17 | 2018-05-23 | Kineta Viral Hemorrhagic Fever, LLC | Antiviral drugs for treatment of arenavirus infection |
| WO2014044611A1 (en) | 2012-09-20 | 2014-03-27 | Bayer Pharma Aktiengesellschaft | 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration |
| CA3008019A1 (en) * | 2015-12-15 | 2017-06-22 | The Board Of Trustees Of The Leland Stanford Junior University | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
| RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4430502A (en) * | 1982-08-13 | 1984-02-07 | The Upjohn Company | Pyridinyl substituted benzimidazoles and quinoxalines |
| ES2113898T3 (es) * | 1991-06-24 | 1998-05-16 | Neurosearch As | Compuestos de imidazol, su fabricacion y utilizacion. |
| MX9203323A (es) * | 1991-07-11 | 1994-07-29 | Hoechst Ag | El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales. |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE4330959A1 (de) * | 1993-09-09 | 1995-03-16 | Schering Ag | Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| IL113472A0 (en) * | 1994-04-29 | 1995-07-31 | Lilly Co Eli | Non-peptidyl tachykinin receptor antogonists |
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| AU6966696A (en) * | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6025379A (en) * | 1996-03-11 | 2000-02-15 | Eli Lilly And Company | Methods of treating or preventing interstitial cystitis |
-
2001
- 2001-01-12 PL PL356091A patent/PL209573B1/pl unknown
- 2001-01-12 NZ NZ519326A patent/NZ519326A/en not_active IP Right Cessation
- 2001-01-12 JP JP2001551855A patent/JP2003523961A/ja active Pending
- 2001-01-12 WO PCT/EP2001/000334 patent/WO2001051473A1/de active IP Right Grant
- 2001-01-12 MX MXPA02005742A patent/MXPA02005742A/es active IP Right Grant
- 2001-01-12 KR KR1020027009085A patent/KR100703908B1/ko not_active IP Right Cessation
- 2001-01-12 EE EEP200200390A patent/EE05515B1/xx not_active IP Right Cessation
- 2001-01-12 RS YU45702A patent/RS51860B/sr unknown
- 2001-01-12 CZ CZ20022420A patent/CZ303726B6/cs not_active IP Right Cessation
- 2001-01-12 AT AT01915133T patent/ATE520669T1/de active
- 2001-01-12 SI SI200131004T patent/SI1246808T1/sl unknown
- 2001-01-12 CN CNB018037666A patent/CN1301975C/zh not_active Expired - Fee Related
- 2001-01-12 ES ES01915133T patent/ES2372026T3/es not_active Expired - Lifetime
- 2001-01-12 IL IL15015001A patent/IL150150A0/xx unknown
- 2001-01-12 ME MEP-133/08A patent/MEP13308A/xx unknown
- 2001-01-12 EA EA200200742A patent/EA006302B1/ru not_active IP Right Cessation
- 2001-01-12 DK DK01915133.1T patent/DK1246808T3/da active
- 2001-01-12 SK SK1000-2002A patent/SK287527B6/sk not_active IP Right Cessation
- 2001-01-12 CA CA2396227A patent/CA2396227C/en not_active Expired - Fee Related
- 2001-01-12 HU HU0204011A patent/HU228366B1/hu not_active IP Right Cessation
- 2001-01-12 EP EP01915133A patent/EP1246808B1/de not_active Expired - Lifetime
- 2001-01-12 PT PT01915133T patent/PT1246808E/pt unknown
- 2001-01-12 BR BR0107628-0A patent/BR0107628A/pt not_active IP Right Cessation
- 2001-01-12 AU AU42332/01A patent/AU782993B2/en not_active Ceased
- 2001-01-12 TW TW090100751A patent/TWI287005B/zh not_active IP Right Cessation
- 2001-12-01 UA UA2002086720A patent/UA75589C2/uk unknown
-
2002
- 2002-06-11 IL IL150150A patent/IL150150A/en not_active IP Right Cessation
- 2002-06-13 BG BG106821A patent/BG65858B1/bg unknown
- 2002-07-12 NO NO20023362A patent/NO326408B1/no not_active IP Right Cessation
- 2002-08-13 HR HR20020664A patent/HRP20020664B1/xx not_active IP Right Cessation
- 2002-08-13 ZA ZA200206470A patent/ZA200206470B/xx unknown
-
2011
- 2011-11-16 CY CY20111101101T patent/CY1112962T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL150150A0 (en) | 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation | |
| TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
| EE200400020A (et) | Asendatud oksasolidinoonid kombineeritud raviks | |
| UA74346C2 (uk) | Похідні амінодикарбонових кислот, їх застосування та лікарський засіб | |
| MX2007003330A (es) | Derivados heterociclicos y su uso como agentes terapeuticos. | |
| TW200505483A (en) | New medicament compositions based on anticholinergically-effective compounds and β-mimetics | |
| IL161156A0 (en) | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity | |
| DE60022226D1 (de) | Benzimidazolverbindungen die nociceptinrezeptoraffinität haben | |
| MXPA05011707A (es) | Dihidroquinazolinas sustituidas con propiedades antivirales. | |
| WO2002010152A3 (de) | Neue indolderivate und deren verwendung als arzneimittel | |
| NZ524742A (en) | Bridged piperazine derivatives | |
| MY133107A (en) | Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia | |
| MX9700959A (es) | Derivados de becimidazol que tienen actividad dopaminergica. | |
| SE0004101D0 (sv) | New use | |
| MXPA04001847A (es) | Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad. | |
| HK1044467A1 (en) | Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity | |
| IL161116A0 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
| TR200302134T4 (tr) | 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı. | |
| TR200102009T2 (tr) | Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı | |
| YU30602A (sh) | Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima | |
| IL160605A (en) | Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity | |
| MXPA04001853A (es) | Uso de sistemas de indan-1-ona c2-substituida para producir medicamentos para la profilaxis o tratamiento de obesidad. | |
| MXPA03003466A (es) | Derivados de piranosido. | |
| DE50112512D1 (de) | Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel | |
| ES2093515T3 (es) | Aplicacion del riluzol como radio-restaurador. |